TEST:

Galen™ Prostate

Although further improvements are required to accurately differentiate rare cancer subtypes, these findings highlight the potential of these algorithms to enhance the precision and efficiency of prostate and breast cancer diagnosis in Japan. Furthermore, this validation paves the way for broader adoption of these algorithms as decision support tools within the Asian population.

P=N/A, N=750, Recruiting, Imperial College London | Trial completion date: Mar 2023 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Jul 2024

"These studies, highlighting the value of Ibex's AI-powered cancer diagnostics...A study conducted at Brigham and Women's Hospital and Champalimaud Foundation evaluated Galen Breast's performance in identifying microinvasive carcinoma of the breast in a challenging patient cohort. Microinvasive carcinoma is defined as the focus of invasive breast cancer no larger than 1mm, in which accurate detection has important implications for patient management. The results indicate that Galen Breast's AI algorithm is highly accurate in detecting microinvasive lesions and has the potential to improve consistency in diagnosis and support more efficient workflows in pathology laboratories...The study found the AI-powered solution was highly accurate in identifying and grading cancer in a live clinical setting, with NPV and PPV of 0.99....Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755."